Progressive supranuclear palsy (PSP) is an adult-onset tauopathy and neurodegenerative disease that is growing in recognition and prevalence [1]. PSP is currently incurable [2]. Therefore, the development of PSP therapies is a highly relevant area of research, and this review summarizes the therap...
We discuss the progress made and future challenges for gene therapy and contrast gene therapy with gene-editing strategies.This is a preview of subscription content, access via your institution Access optionsAccess Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-...
Ethylmalonic encephalopathy (EE) is a severe monogenic disorder caused by mutations of the nuclear geneETHE1, encoding a ubiquitous mitochondrial protein sulfur dioxygenase (SDO) (note: EE is not classified as MD) [131], involved in the detoxification of H2S [132,133] showed that AAV2/8-medi...
Smart nanoparticles, which can respond to biological cues or be guided by them, are emerging as a promising drug delivery platform for precise cancer treatment. The field of oncology, nanotechnology, and biomedicine has witnessed rapid progress, leading to innovative developments in smart nanoparticles ...
Template A review should describe an overview of recent progress in important fields of research, providing an appreciation of the significance of the work, and an outlook into potential future directions. Unstructured abstract ≤ 300 words
progress that has been made to date using patient-derived neurons to recapitulate key aspects of AD pathology and how these models have contributed to a deeper understanding of AD molecular mechanisms, as well as addressing the key challenges posed by using this technology and what progress is ...
Depending on the trial progress, it may be useful to purposefully sample and interview a range of individual participants; for example, participants who have dropped out of the programme, participants who have not responded to the programme, participants who have responded well to the programme etc...
However, it was important to note that this analysis was not a comparison of efficacy. While LITT may have a cost advantage, assertions could not be made at this time regarding which modality is more effective in prolonging the life of the patient. It was assumed that patients discharged ...
Close Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily. Email address Sign up I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy....
et al. KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC. Future Oncol. 16, 507–516 (2020). Article CAS PubMed Google Scholar Lamm, D. L. Intravesical therapy for superficial bladder cancer: slow but steady progress. J. Clin. Oncol. 21, ...